Visibility of prostate cancer on transrectal ultrasound during fusion with multi-parametric magnetic resonance imaging for biopsy

W. van de Ven, J. Sedelaar, M. van der Leest, C. de Hulsbergen-van Kaa, J. Barentsz, J. Futterer and H. Huisman

Clinical Imaging 2016;40(4):745-750.

DOI PMID Cited by ~21

Objectives

To determine TRUS visibility of MR lesions.

Methods

Data from 34 patients with 56 MR lesions and prostatectomy was used. Five observers localized and determined TRUS visibility during retrospective fusion. Visibility was correlated to PIRADS and Gleason scores.

Results

TRUS visibility occurred in 43% of all MR lesions and 62% of PIRADS 5 lesions. Visible lesions had a significantly lower localization variability. On prostatectomy, 58% of the TRUS visible lesions had a Gleason 4 or 5 component.

Conclusions

Almost half of the MR lesions were visible on TRUS. TRUS visible lesions were more aggressive than TRUS invisible lesions.